BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 4126273)

  • 21. [Treatment of juvenile rheumatic arthritis (chronic polyarthritis) with Indomethacin].
    Stoeber E; Sänger L; Kölle G
    Munch Med Wochenschr; 1968 Mar; 110(9):548-51. PubMed ID: 5695261
    [No Abstract]   [Full Text] [Related]  

  • 22. [Combined immunosuppressive-antiphlogistic therapy of chronic rheumatic diseases].
    Tanner E; Siering H; Keil K
    Arzneimittelforschung; 1970 Nov; 20(11):1804-6. PubMed ID: 5536997
    [No Abstract]   [Full Text] [Related]  

  • 23. [Quantitative determination of C-reactive protein in progressive chronic polyarthritis].
    Frank O
    Verh Dtsch Ges Rheumatol; 1974; 3(0):54-5. PubMed ID: 4134651
    [No Abstract]   [Full Text] [Related]  

  • 24. [Serum complement reduction in chronic progressive polyarthritis. II. Behavior of serum complement in the disease course].
    Fehr K; Böni A
    Z Rheumaforsch; 1972; 31(1):12-25. PubMed ID: 4111720
    [No Abstract]   [Full Text] [Related]  

  • 25. [Assessment of inflammatory activity in chronic polyarthritis using radioactive isotopes].
    Kolarz G
    Acta Med Austriaca Suppl; 1977; 7():1-24. PubMed ID: 266822
    [No Abstract]   [Full Text] [Related]  

  • 26. [Morphology, significance and demonstration methods of LE cells and pseudo-LE cells as well as the frequency of their occurrence in patients with primary chronic polyarthritis].
    Böhme A; Schedwill K; Gössel G
    Z Gesamte Inn Med; 1969 Jul; 24(14):424-32. PubMed ID: 4187497
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of progressive chronic polyarthritis with cytostatic agents].
    Jesserer H
    Wien Klin Wochenschr; 1968 Mar; 80(10):187-91. PubMed ID: 5650710
    [No Abstract]   [Full Text] [Related]  

  • 28. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
    St Clair EW; Moak SA; Wilkinson WE; Sanders L; Lang T; Greenwald RA
    J Rheumatol; 1998 Aug; 25(8):1472-9. PubMed ID: 9712086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary chronic polyarthritis and diabetes mellitus].
    Weigl E
    Z Gesamte Inn Med; 1970 Jul; 25(14):621-5. PubMed ID: 5516162
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis.
    McConkey B; Crockson RA; Crockson AP; Wilkinson AR
    Q J Med; 1973 Oct; 42(168):785-91. PubMed ID: 4370457
    [No Abstract]   [Full Text] [Related]  

  • 31. [Preliminary report on experience with immunosuppressive therapy in progressive chronic (rheumatoid) polyarthritis and collagen diseases].
    Schuster F; Beier A; Eberl R; Tausch G
    Z Rheumaforsch; 1969; 28(1):12-20. PubMed ID: 5810410
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of primary chronic polyarthritis with a cytostatic agent of the ethyleneimine group].
    Cruz A
    Z Rheumaforsch; 1970; 29(3):120-4. PubMed ID: 5528257
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunosuppressive treatment of progressive chronic polyarthritis].
    Seidel R; Reissmann K; Land H; Rödel J
    Z Gesamte Inn Med; 1975 Aug; 30(16):535-8. PubMed ID: 1189506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Erythrocytes in active chronic progressive polyarthritis. II. Erythrocyte survival time].
    Neumann W; Tanner E; Ebner E; Unverricht A; Correns HJ
    Dtsch Gesundheitsw; 1970 Feb; 25(5):206-10. PubMed ID: 5448556
    [No Abstract]   [Full Text] [Related]  

  • 35. Benorylate and indomethacin in the treatment of rheumatoid disease: a double-blind clinical trial.
    Franke M; Manz G
    Curr Ther Res Clin Exp; 1972 Mar; 14(3):113-22. PubMed ID: 4622890
    [No Abstract]   [Full Text] [Related]  

  • 36. [Problems of immunosuppressive therapy as shown on the example of chronic progressive polyarthritis].
    Jesserer H
    Z Gesamte Inn Med; 1973 Mar; 28(5):68-70. PubMed ID: 4705899
    [No Abstract]   [Full Text] [Related]  

  • 37. [Influencing of the immunosuppressive treatment (trenimon) upon the human-gammaglobulin-skintest in patients with chronic progressive polyarthritis (author's transl)].
    Dölitzscher G; Siering H
    Folia Clin Int (Barc); 1974 Jan; 24(1):64-72. PubMed ID: 4131812
    [No Abstract]   [Full Text] [Related]  

  • 38. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Behavior of serum proteins in rheumatoid arthritis. II. Types of pathological proteinograms. Significance of alpha2 hyperglobulinemia and hypergammaglobulinemia for evaluation of the course of rheumatoid arthritis].
    Brzezińska B
    Reumatologia; 1969; 7(2):133-8. PubMed ID: 4186493
    [No Abstract]   [Full Text] [Related]  

  • 40. [Study of lysozyme in the blood, urine and synovial fluid in different stages of rheumatoid polyarthritis and under the influence of therapy].
    Georgesco C; Serban M; Gheorghiu M
    Med Interne; 1981; 19(1):51-4. PubMed ID: 7233047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.